Monthly Archives: August 2025

Dapagliflozin 5mg and 10mg tablets reimbursement prices have decreased following a move from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. More information on the [...]

The post Dapagliflozin tablets – new reimbursement prices from September 2025 appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 September 2025. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution [...]

The post Drug Tariff Watch – September 2025 appeared first on Community Pharmacy England.

Community Pharmacy England has today released a national report highlighting how pharmacy owners across England are dipping into personal savings to support their businesses, effectively subsidising the provision of NHS services. The Pharmacy Pressures Survey 2025: Funding and Profitability Report sets out once again the desperate financial position community pharmacies are in as a result of [...]

The post Pharmacy owners subsidising NHS services, Pressures Survey shows appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following product: Repaglinide 500microgram,1mg and 2mg tablets MSN/2025/050 Tier 2 – medium impact Date of issue: 26/08/2025 Repaglinide 500microgram and 1mg tablets will be out of stock from late August until early December 2025 Repaglinide 2mg tablets are in [...]

The post Medicine Supply Notification: Repaglinide 500microgram,1mg and 2mg tablets appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Notification: Various Products (Ipca Laboratories UK Limited) Date issued: 26 August 2025 Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information. DMRC reference number: DMRC-35766519 Marketing Authorisation Holder: Ipca Laboratories UK [...]

The post MHRA Class 4 Medicines Notification Various Products (Ipca Laboratories UK Limited) appeared first on Community Pharmacy England.